|Study Description:||The goal of this clinical research study is to learn if 2 different doses of |
brentuximab vedotin, when combined with standard chemotherapy, can help to
control DLBCL. The safety of this drug combination will also be studied.
The standard chemotherapy used in this study is called RCHOP, which is a
combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and
Brentuximab vedotin is designed to attach to a protein called CD30, which may
cause these cells to die. CD30 is found on some normal cells in the body’s
immune system and on some types of cancer cells.